Skip to Content

Surmax 200 Premix (Canada)

This page contains information on Surmax 200 Premix for veterinary use.
The information provided typically includes the following:
  • Surmax 200 Premix Indications
  • Warnings and cautions for Surmax 200 Premix
  • Direction and dosage information for Surmax 200 Premix

Surmax 200 Premix

This treatment applies to the following species:
Manufacturer: Elanco

avilamycin premix 200 g/kg

DIN 02436760

FOR VETERINARY USE ONLY

FOR USE IN SWINE FEEDS ONLY

ACTIVE DRUG INGREDIENT:

avilamycin

200 g per kg of premix

DESCRIPTION:

Avilamycin is an antibiotic of the orthosomycin family produced by fermentation of Streptomyces viridochromogenes. Orthosomycin antibiotics are divided into two groups: those that contain an aminocyclitol residue and those that are esters of dichlorisoeverninic acid. Avilamycin falls into the latter group as do the everninomicins.

Avilamycin inhibits bacterial protein synthesis through a novel mechanism of action by binding to the 50S ribosomal subunit and preventing the association of initiation factor IF2, which inhibits the formation of the mature 70S initiation complex, and the correct positioning of tRNA in the aminoacyl site.

ACTIVITY:

Avilamycin is primarily active against gram-positive bacteria and lacks antibacterial activity for gram-negative bacteria (including Escherichia coli) as determined by antimicrobial susceptibility testing. Avilamycin does not exhibit bactericidal or bacteriostatic activity against E. coli with the MIC value of >128 µg/mL. Hence, E. coli is intrinsically resistant to avilamycin. However, in vitro experiments have suggested that avilamycin may reduce the production of pili on the surface of E. coli. Exposure of E. coli to avilamycin may limit the number of adhesive pili and reduce the attachment of bacteria to the intestinal mucosa, thereby preventing the intestinal damage that leads to diarrhea observed in weaned pigs.

INDICATION:

For reduction in incidence and severity of post-weaning diarrhea associated with Escherichia coli in pigs. Avilamycin is to be used in pigs that are at risk of developing, but not yet showing clinical signs of, diarrhea in the presence of pathogenic E. coli.

Notes:

1. Comprehensive management of diarrhea due to E. coli should be planned in consultation with veterinary and nutritional swine expertise.

2. As Surmax 200 Premix is only indicated for use in weanling pigs, responsible antimicrobial use limits its use to pigs less than 14 weeks of age.

DOSAGE AND ADMINISTRATION:

MIXING DIRECTIONS:

Thoroughly mix 0.40 kg of Surmax 200 Premix per 1000 kg of feed to yield 80 ppm of avilamycin.

IMPORTANT: Must be thoroughly mixed in swine feed before use.

For better dispersion, it is recommended that Surmax 200 Premix be thoroughly mixed with a small quantity of the feed ingredients (totalling at least 10 kg) prior to the manufacturing of the medicated feed.

FEEDING DIRECTIONS:

Avilamycin should be fed as a sole ration continuously at 80 ppm for a period of up to 21 days post weaning, and prior to the expected onset of post-weaning diarrhea (See Caution).

CAUTIONS:

The effectiveness of Surmax 200 Premix has only been demonstrated when avilamycin-medicated feed was offered before the onset of diarrhea. Use of Surmax 200 Premix for the treatment of established cases of clinical diarrhea in weanling pigs has not been demonstrated.

WARNINGS:

No preslaughter withdrawal periods are required for swine when treated according to the label.

Do not use in laying hens.

Avoid inhalation, oral exposure, and direct contact with skin or eyes. Operators mixing and handling Surmax 200 Premix should use protective clothing, impervious gloves, goggles, and an approved dust mask. Wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse thoroughly with water. If irritation persists, seek medical attention.

Keep out of reach of children.

EFFECTIVENESS:

A randomized, controlled, blinded clinical trial was performed in 2011 at four swine farms in the USA. A total of 800 weanling pigs enrolled in the trial (200 animals per site, 100 treated with Surmax 200 Premix at 80 ppm in feed for 21 days and 100 negative control pigs). All pigs were 3 - 4 weeks of age when weaned and enrolled in the trial.

The primary outcome parameter was incidence of diarrhea during the 21-day study period. Fecal consistency was assessed for each animal daily, using a 4-point scale (0 = normal feces, 1 = semi-solid feces, 2 = loose feces, 3 = watery feces). An animal was considered diarrheic if it had a fecal consistency score of 2 or 3 at any point during the 21-day study period. The secondary outcome parameter was severity of diarrhea, based on the mean diarrhea score during the study period. Animals removed from the study for non-colibacillosis reasons were excluded from the diarrhea incidence and severity analysis.

Avilamycin-treated pigs had an overall 21-day diarrhea incidence that was 31% lower than the negative-control group. This difference was statistically significant (p<0.01). The overall absolute reduction in diarrhea incidence was 28% (Surmax 200 Premix incidence = 61%, control incidence = 89%). Avilamycin-treated animals at all 4 sites had a lower incidence of diarrhea than negative controls. See table below for further details.

The overall mean diarrhea severity scores for avilamycin treatment group and negative control were 0.43 and 0.87, respectively. This difference is statistically significantly different (p<0.01).

Location

GROUP

Diarrhea Incidence during 21-day study period (%)

Absolute Risk Reduction (ARR) (Control - Surmax)

Relative Risk Reduction (ARR / control)

Iowa

Control

89

43%

48%

 

Surmax 200

46

Iowa

Control

95

28%

29%

 

Surmax 200

67

Nebraska

Control

95

8%

8%

 

Surmax 200

87

California

Control

76

33%

43%

 

Surmax 200

43

COMBINED

Control

89

28%

31%

 

Surmax 200

61

STORAGE:

Store at or below 25°C.

Elanco, Surmax and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

ELANCO, Division Eli Lilly Canada Inc., 150 Research Lane, Suite 120, Guelph, Ontario, N1G 4T2

Net:

 

 

25 kg

AF0520

Revised 30-Jan-15

NAC No.: 1184058.0

ELANCO, Division Eli Lilly Canada Inc. & ELANCO CANADA LIMITED (successor to Novartis Animal Health Canada Inc.)
RESEARCH PARK CENTRE, 150 RESEARCH LANE, SUITE 120, GUELPH, ON, N1G 4T2
Telephone:   519-821-0277
Order Desk:   800-773-7603
Fax:   519-821-7831
Elanco Canada Limited Customer Service Telephone:   800-387-6325
Elanco Canada Limited Customer Service Fax:   800-827-5782
Website:   www.Elanco.ca
Every effort has been made to ensure the accuracy of the Surmax 200 Premix information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-10-31

Hide